Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia

Abstract

We retrospectively analyzed the relationship between white blood cell (WBC) count elevation after priming and clinical response in 115 patients with AML (61 untreated and 54 relapsed or refractory) treated with low-dose cytarabine, aclarubicin, and G-CSF priming. Receiver operating characteristic curve analysis showed that the ratio of maximum WBC count to pretreatment WBC count (WBCratio) was most strongly associated with complete remission (CR) in previously untreated patients among several parameters we analyzed in this study; however, the prediction accuracy was not clinically significant considering the area under the curve of 0.694. Based on the cutoff value of the WBCratio, CR rate and event-free survival in the high WBCratio group were significantly better than those in the low WBCratio group in untreated patients. Regarding the WBC differential counts, a high ratio of the maximum to pretreatment value of neutrophils rather than that of peripheral blasts was associated with a superior CR rate. In addition, an increase in blasts after G-CSF priming had a significant negative impact on CR rate in untreated patients. In conclusion, an increase in blast counts after G-CSF priming was not predictive of achieving CR.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127:53–61.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–24.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9:10–4.

    CAS  PubMed  Google Scholar 

  4. 4.

    Zhu HH, Jiang H, Jiang B, Lu J, Jiang Q, Bao L, et al. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Leuk Lymphoma. 2013;54:2452–7.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011;4:46–58.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Li JM, Shen Y, Wu DP, Liang H, Jin J, Chen FY, et al. Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol. 2005;82:48–54.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Liu L, Zhang Y, Jin Z, Zhang X, Zhao G, Si Y, et al. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Int J Hematol. 2014;99:603–8.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Fukushima T, Kawabata H, Sawaki T, Satoh T, Nakamura T, Iwao H, et al. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline. Anticancer Res. 2012;32:1347–53.

    CAS  PubMed  Google Scholar 

  9. 9.

    Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: a propensity score analysis. Leuk Res. 2016;42:82–7.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, et al. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia. Leuk Lymphoma. 2015;56:1691–7.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Saito K, Nakamura Y, Aoyagi M, Waga K, Yamamoto K, Aoyagi A, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol. 2000;71:238–44.

    CAS  PubMed  Google Scholar 

  12. 12.

    Lowenberg B, van Putten W, Theobald M, Gmur J, Verdonck L, Sonneveld P, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743–52.

    Article  PubMed  Google Scholar 

  13. 13.

    Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood. 2012;119:5367–73.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27–34.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Swerdlow SH, Harris NL, Campo E. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  16. 16.

    Dohner H, Estey H, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74.

    Article  PubMed  Google Scholar 

  17. 17.

    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64–70.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Rutella S, Bonanno G, Procoli A, Mariotti A, Lucia MB, Contemi AM, et al. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Exp Hematol. 2006;34:54–65.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yoshinobu Kanda.

Ethics declarations

Conflict of interest

We declare that we have no conflicts of interest.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Minakata, D., Fujiwara, S., Ikeda, T. et al. Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia. Int J Hematol 106, 411–417 (2017). https://doi.org/10.1007/s12185-017-2251-z

Download citation

Keywords

  • G-CSF
  • G-CSF priming chemotherapy
  • Acute myeloid leukemia